<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="133351">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01365793</url>
  </required_header>
  <id_info>
    <org_study_id>200917444-1</org_study_id>
    <secondary_id>U01HD062417</secondary_id>
    <nct_id>NCT01365793</nct_id>
  </id_info>
  <brief_title>Randomized Control Trial of Fluid Therapy for Pediatric Diabetic Ketoacidosis</brief_title>
  <official_title>Fluid Therapy and Cerebral Injury in Pediatric Diabetic Ketoacidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will conduct a randomized controlled trial comparing four different
      intravenous (IV) fluid treatment protocols for pediatric diabetic ketoacidosis (DKA). Two
      rates of rehydration will be compared; a more rapid rate and a slower rate. Within each of
      these two basic rehydration protocols, the investigators will vary the type of rehydration
      fluid used (0.9% saline or 0.45% saline). The investigators will compare the different
      treatments by conducting assessments of neurological injury, by measuring the frequency of
      significant cerebral edema, and by measuring long-term neurocognitive function.

      These studies will allow us to determine whether variations in IV fluid treatment protocols
      affect acute neurological outcomes of DKA. Additionally, they will provide important data
      regarding the impact of DKA and DKA treatment on long-term neurocognitive function in
      children. In this way, the investigators hope to identify a more ideal fluid management
      strategy for children with DKA.

      Previous studies have suggested that DKA may cause blood flow to the brain to be reduced and
      that brain injury might result from this reduction in blood flow and/or the effects of
      re-establishment of normal blood flow during DKA treatment with insulin and iv fluids. The
      investigators hypothesize that more rapidly re-establishing normal blood flow to the brain
      during DKA, by giving fluids more rapidly and using fluids with a higher sodium (salt)
      content, will help to minimize brain injury caused by DKA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      These data will be compared to observational data from children with type 1 diabetes without
      DKA.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glasgow Coma Score &lt; 14 within the first 24 hours of treatment for DKA.</measure>
    <time_frame>24 hours</time_frame>
    <description>The primary outcome is the binary indicator that a patient's GCS score drops below 14 (i.e. abnormal score) within the first 24 hours of treatment of DKA. There will be two treatment factors: sodium concentration of re-hydration fluids and rate of rehydration. These effects will be tested separately, using the Mantel-Haenszel chi-square test, stratified by hospital, and by the other main factor.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of clinically apparent cerebral edema during DKA treatment</measure>
    <time_frame>24 hours</time_frame>
    <description>GCS scores between the 4 groups will be compared using a Wilcoxon rank- sum test or a Van Elteren test, stratified by hospital. Patients presenting with GCS scores &lt; 14 will be included in this analysis. The outcome will be difference between GCS score at presentation and lowest recorded GCS score, with death as the worst possible ranking.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median scores on digit span testing during DKA treatment</measure>
    <time_frame>24 hours</time_frame>
    <description>Digit span scores are measured as the longest span correctly recited in each of the assessment sessions. Separate analyses will be conducted for the forward and backward spans. Digit span scores can be analyzed using para- metric methods. The trajectory of digit span scores during the course of the hospitalization can be used to assess patients rates of recovery and whether this rate varies systematically as a function of treatment protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean scores on tests of memory capacity 3 months after recovery from DKA.</measure>
    <time_frame>3 months</time_frame>
    <description>The effects of treatment conditions on memory function will be examined in separate analyses of variance (ANOVA) in which each of the indices of the memory performance will be considered as outcomes. The proposed memory tasks yield two indices of performance, recollection of item-context associations and item recognition. Memory function after recovery from DKA will also be compared with memory function of children with type 1 diabetes without DKA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean scores on IQ tests 3 months after recovery from DKA</measure>
    <time_frame>3 months</time_frame>
    <description>The same analytical approach proposed for memory will be used for the analyses of IQ measures. Each test will provide three scores: a verbal IQ, and performance IQ, and a total IQ score. Each of these three IQ measures will be analyzed using ANOVA. Mean IQ scores will also be compared with IQ scores of children with type 1 diabetes without DKA.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">1510</enrollment>
  <condition>Cerebral Edema</condition>
  <condition>Diabetic Ketoacidosis</condition>
  <arm_group>
    <arm_group_label>Rapid rehydration using 0.45% saline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will involve more rapid intravenous fluid treatment which will include a second 10cc/Kg bolus of 0.9% saline and assume a 10% fluid deficit. 0.45% saline will be used as the replacement fluid for this arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rapid rehydration using 0.9% saline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will involve more rapid intravenous fluid treatment which will include a second 10cc/Kg bolus of 0.9% saline and assume a 10% fluid deficit. 0.9% saline will be used as the replacement fluid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Slower rehydration using 0.45% saline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will involve slower rehydration (assumed 5% fluid deficit and no additional fluid bolus) with 0.45% saline used as the replacement fluid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Slower rehydration using 0.9% saline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will involve slower rehydration (assumed 5% fluid deficit and no additional fuid bolus) with 0.9% saline used as the replacement fluid.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intravenous fluid</intervention_name>
    <description>10cc/Kg bolus of 0.9% saline followed by 0.45% saline used as the replacement fluid</description>
    <arm_group_label>Rapid rehydration using 0.45% saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>intravenous fluid</intervention_name>
    <description>10cc/Kg bolus of 0.9% saline followed by 0.9% saline used as the replacement fluid.</description>
    <arm_group_label>Rapid rehydration using 0.9% saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>intravenous fluid</intervention_name>
    <description>0.45% saline fluid</description>
    <arm_group_label>Slower rehydration using 0.45% saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intravenous fluid</intervention_name>
    <description>0.9% saline fluid</description>
    <arm_group_label>Slower rehydration using 0.9% saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  must present or be transferred to a participating emergency department

          -  age less than 18 years

          -  diagnosis of DKA

               -  serum glucose or fingerstick glucose concentration &gt;300 mg/dL

               -  venous pH &lt; 7.25 OR serum bicarbonate concentration &lt; 15 mmol/L.

        Exclusion Criteria:

          -  patients with underlying neurological disorders or neurocognitive deficits which
             would affect either mental status testing during treatment or subsequent
             neurocognitive testing after recovery

          -  patients who present with concomitant alcohol or drug use, head trauma, meningitis or
             other conditions which might affect neurological function

          -  patients transferred to one of the participating emergency departments after
             initiation of DKA treatment other than one 10cc/kg intravenous bolus of 0.9% saline

          -  patients who are known to be pregnant at time of ED evaluation

          -  patients who have been enrolled in this study twice previously

          -  patients for whom the treating physician believed a specific fluid and electrolyte
             regimen was warranted

          -  patients for whom informed consent could not be obtained within 1 hour after
             completion of the initial fluid bolus, or within 2 hours from initiation of fluids,
             whichever is longer

          -  Patients who have been receiving IV fluids at a maintenance rate or greater (defined
             by the 4-2-1 rule) for more than two hours; OR

          -  Patients for whom it has been more than four hours since DKA therapy (IV fluids, IV
             bolus, or IV insulin) began; OR

          -  Patients who have been given hyperosmolar therapy (i.e. mannitol or 3% normal saline)
             prior to or since arriving at one of the participating PECARN emergency departments;
             OR

          -  Patients for whom the treating physician intends to immediately administer
             hyperosmolar therapy (i.e. mannitol or 3% normal saline); OR

          -  Patients whose baseline GCS is 11 or less.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nathan Kuppermann, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicole S Glaser, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nathan Kuppermann, MD, MPH</last_name>
    <phone>916-734-1535</phone>
    <email>nkuppermann@ucdavis.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicole S Glaser, MD</last_name>
    <phone>916-734-0406</phone>
    <email>nsglaser@ucdavis.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California, Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathan Kuppermann, MD, MPH</last_name>
      <phone>916-734-1535</phone>
      <email>nkuppermann@ucdavis.edu</email>
    </contact>
    <contact_backup>
      <last_name>Nicole S Glaser, MD</last_name>
      <phone>916-734-0406</phone>
      <email>nsglaser@ucdavis.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Nathan Kuppermann, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicole S Glaser, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arleta Rewers, MD</last_name>
      <phone>303-724-2576</phone>
      <email>arleta.rewers@childrenscolorado.org</email>
    </contact>
    <contact_backup>
      <last_name>Lalit Bajaj, MD</last_name>
      <email>lalit.bajaj@childrenscolorado.org</email>
    </contact_backup>
    <investigator>
      <last_name>Arleta Rewers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alfred I. duPont Hospital for Children</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Brown, MD</last_name>
      <phone>202-476-4177</phone>
      <email>kbrown@childrensnational.org</email>
    </contact>
    <contact_backup>
      <last_name>James Chamberlain, MD</last_name>
      <email>jchamber@childrensnational.org</email>
    </contact_backup>
    <investigator>
      <last_name>Kathleen Brown, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Trainor, MD</last_name>
      <phone>773-880-8245</phone>
      <email>jtrainor@luriechildrens.org</email>
    </contact>
    <contact_backup>
      <last_name>Elizabeth Powell, MD</last_name>
      <phone>773-880-4000</phone>
      <email>epowell@luriechildrens.org</email>
    </contact_backup>
    <investigator>
      <last_name>Jennifer Trainor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lise E Nigrovic, MD, MPH</last_name>
      <phone>617-355-6000</phone>
      <email>lise.nigrovic@childrens.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Lise E Nigrovic, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University &amp; St. Louis Children's Hospital</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Quayle, MD</last_name>
      <phone>314-454-2341</phone>
      <email>quayle@kids.wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>David Jaffe, MD</last_name>
      <phone>314-454-2341</phone>
      <email>jaffe@kids.wustl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kimberly Quayle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York City</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Kwok, MD</last_name>
      <phone>212-305-8319</phone>
      <email>myk2102@columbia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Peter S Dayan, MD</last_name>
      <phone>212-342-4176</phone>
      <email>psd9@columbia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Maria Kwok, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>John S Baird, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael J Stoner, MD</last_name>
      <phone>614-722-4385</phone>
      <email>michael.stoner@nationwidechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Michael J Stoner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sage Myers, MD</last_name>
      <phone>215-590-1944</phone>
      <email>myerss@email.chop.edu</email>
    </contact>
    <contact_backup>
      <last_name>Joseph Zorc, MD</last_name>
      <phone>215-590-1944</phone>
      <email>zorc@email.chop.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Sage Myers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hasbro Children's Hospital/Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aris Garro, MD, MPH</last_name>
      <phone>401-444-4900</phone>
      <email>arisgarro1@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Aris Garro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie McManemy, MD</last_name>
      <phone>832-824-5497</phone>
      <email>jkmcmane@texaschildrens.org</email>
    </contact>
    <contact_backup>
      <last_name>Charles G Macias, MD, MPH</last_name>
      <phone>832.824.5416</phone>
      <email>cgmacias@texaschildrens.org</email>
    </contact_backup>
    <investigator>
      <last_name>Julie McManemy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeff Schunk, MD</last_name>
      <phone>801-587-7427</phone>
      <email>jeff.schunk@hsc.utah.edu</email>
    </contact>
    <contact_backup>
      <last_name>Douglas Nelson, MD</last_name>
      <phone>801-587-7450</phone>
      <email>doug.nelson@hsc.utah.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jeff Schunk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.pecarn.org</url>
    <description>Official website of the Pediatric Emergency Care Applied Research Network (PECARN), funded by HRSA/MCHB</description>
  </link>
  <reference>
    <citation>Glaser NS, Ghetti S, Casper TC, Dean JM, Kuppermann N; Pediatric Emergency Care Applied Research Network (PECARN) DKA FLUID Study Group.. Pediatric diabetic ketoacidosis, fluid therapy, and cerebral injury: the design of a factorial randomized controlled trial. Pediatr Diabetes. 2013 Sep;14(6):435-46. doi: 10.1111/pedi.12027. Epub 2013 Mar 13.</citation>
    <PMID>23490311</PMID>
  </reference>
  <verification_date>May 2016</verification_date>
  <lastchanged_date>May 10, 2016</lastchanged_date>
  <firstreceived_date>June 1, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cerebral edema</keyword>
  <keyword>diabetic ketoacidosis</keyword>
  <keyword>pediatric diabetes</keyword>
  <keyword>fluid therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ketosis</mesh_term>
    <mesh_term>Acidosis</mesh_term>
    <mesh_term>Diabetic Ketoacidosis</mesh_term>
    <mesh_term>Brain Edema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
